E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery |
|
E.1.1.1 | Medical condition in easily understood language |
Malignant peripheral nerve sheath tumor (MPNST) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Main Objective:
To evaluate the percentage of patients with curatively unresectable MPNST who have achieved clinical response; complete response (CR), partial response (PR), or stable disease (SD) at 18 weeks as assessed by the Investigator, by using iRECIST, v1.1.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives:
1)Overall response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), and progression-free survival (PFS), assessed by the Investigator by using RECIST, v1.1.
2) To evaluate the percentage of patients who have achieved clinical response; CR, PR, or SD at 18 weeks , ORR, CBR, DOR, and PFS assessed by the Investigator by using immune-related response criteria, irRC.
3) To evaluate the percentage of patients who have achieved clinical response; CR, PR, or SD at 18 weeks, ORR, CBR, DOR, and PFS assessed by the Investigator by using Immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST)
4) To evaluate overall survival (OS).
5) To evaluate the safety and tolerability of pembrolizumab in patients with MPNST.
6) To evaluate health-related quality of life changes from baseline in patients with MPNST, receiving pembrolizumab, using EORTC-QLQC30.
In addition there are 7 Exploratory Objectives.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male and female subjects of at least 18 years of age with metastatic or locally advanced/unresectable MPNST
1. Be willing and able to provide written informed consent/assent for the trial.
2. Be 18 years of age on day of signing informed consent.
3. Have measurable disease based on RECIST, version 1.1.
4. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.
5. Be willing to provide tissue from a newly obtained core or excisional biopsy of benign nevrofibromatosis lesion (NF1 patients only)
6. Have a performance status of 0 or 1 on the ECOG Performance Scale.
7. Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 10 days of treatment initiation.
8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
9. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 5.7.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
10. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy |
|
E.4 | Principal exclusion criteria |
1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
3. Has a known history of active TB (Bacillus Tuberculosis)
4. Hypersensitivity to pembrolizumab or any of its excipients.
5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
- Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
- Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
7. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
10. Has known history of, or any evidence of active, non-infectious pneumonitis.
11. Has an active infection requiring systemic therapy.
12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
14. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
15. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
18. Has received a live vaccine within 30 days of planned start of study therapy.
Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Clinical response at 18 weeks:
The percentage of patients with unresectable MPNST who have achieved clinical response; complete response (CR), partial response (PR), or stable disease (SD) at 18 weeks as assessed by using RECIST, v1.1. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary efficacy analysis will be percentage of patients with response, defined as CR, PR, or SD, and will be evaluated by the Investigator 18 weeks after start of treatment, according to RECIST, v1.1. |
|
E.5.2 | Secondary end point(s) |
Overall survival (OS):
This is the gold standard endpoint to demonstrate efficacy of antineoplastic therapy.
Progression free survival (PFS):
This may be an acceptable scientific endpoint for clinical trials in oncology. RECIST 1.1 will be used to determine the dates of progression as this methodology is scientifically accepted. The first on-study radiographic imaging assessment will be performed at 9 weeks (±7 days) after first dose of study treatment and then every 6 weeks (±7 days) during treatment, and then every 8 weeks, or more frequently if clinically indicated.
Patient Reported Outcomes:
- Quality of life using EORTC QLQ-C30
- Safety will be assessed by reported adverse experiences using CTCAE, Version 4.0.
-
Planned Exploratory Biomarker Research
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Overall survival (OS) will be calculated from the date of randomization until death. Patients alive at 24 months after last enrolled patient will be treated as censored. OS will be estimated by the Kaplan Meier method.
Progression free survival (PFS) will be measured as the time from first dose of pembrolizumab to the first progression recorded or death. If patients undergo curative surgical resection after start of treatment, PFS will be measured as time from first dose of pembrolizumab to disease recurrence after surgery or death. Patients who have not yet progressed or died 24 months after last enrolled patient will be treated as censored. PFS will be estimated by the Kaplan Meier method.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The overall trial ends when the last subject completes the last study-related phone call or visit, discontinues from the trial or is lost to follow-up (i.e. the subject is unable to be contacted by the investigator). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 9 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 9 |